<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Older patients with Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) have inferior outcomes </plain></SENT>
<SENT sid="1" pm="."><plain>Because <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> is highly active in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and can be dose-escalated without stem-cell rescue, we designed a short, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>-intensive regimen without <z:chebi fb="0" ids="48120">anthracyclines</z:chebi> for patients aged â‰¥ 30 with untreated, non-HIV-associated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/atypical <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Two cycles involving <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 1500 mg/m(2), <z:chebi fb="0" ids="28445">vincristine</z:chebi>, rituximab, <z:chebi fb="0" ids="8382">prednisone</z:chebi>, <z:chebi fb="0" ids="44185">methotrexate</z:chebi> 3 g/m(2), and intrathecal <z:chebi fb="0" ids="28680">cytarabine</z:chebi> were delivered 2 weeks apart, followed by intensification with high-dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (50 mg/kg/day for 4 days) and rituximab </plain></SENT>
<SENT sid="3" pm="."><plain>Of 21 patients, median age 53 (range, 34-75), 71% had stage IV, 95% were high-risk and 29% had performance status 3-4 </plain></SENT>
<SENT sid="4" pm="."><plain>Response occurred in <z:hpo ids='HP_0000001'>all</z:hpo> evaluable patients post-cycle 2 and in 76% post-intensification </plain></SENT>
<SENT sid="5" pm="."><plain>Five non-relapse <z:hpo ids='HP_0011420'>deaths</z:hpo> occurred (four before intensification) </plain></SENT>
<SENT sid="6" pm="."><plain>The estimated 1-year and 3-year event-free survival was 52%; 1-year and 3-year overall survival was 57% </plain></SENT>
<SENT sid="7" pm="."><plain>Seventeen (81%) received intensification (median 30 days to intensification) </plain></SENT>
<SENT sid="8" pm="."><plain>Brief, <z:chebi fb="0" ids="48120">anthracycline</z:chebi>-sparing, intensive <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (BASIC) therapy yields durable remissions in poorer-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/atypical <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
</text></document>